Advertisement

GBS Inc. GBS

Set alert

Price alert · GBS

All alert types
0.47 0.00 0.00%

At close

0.4507 Day range 0.4854

52-week range unavailable

Open
0.4808
Prev close
0.4732
Mkt cap
433.58K
Vol
9.03K
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
0.4507
High
0.4854
Forward P/E
-5.26
Beta
0.00
Short ratio
1.84
Inst. own
2.79%
Dividend
0.00
Ex-div date
Earnings
Aug 31, 2022
50-d avg
0.49918
200-d avg
0.69182
1y target
4.50

2Y chart

Chart tools
Interval

Chart is warming up

The two-year price history for GBS has not been loaded yet. Try again in a moment.

Key statistics

Market cap
7.05M
Enterprise value
-1.32M
Trailing P/E
0.00
Forward P/E
-5.26
PEG ratio
0.00
Price / sales
16.12
Price / book
1.06
EPS (TTM)
-0.502
Beta
0.00
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
437.15K
Revenue growth
-95.80%
Free cash flow
-1.56M
Total cash
8.28M
Total debt
0
Return on equity
-77.34%
Shares outstanding
14.89M
Short % of float
1.02%
50-day average
0.49918
200-day average
0.69182

Analyst view

Consensus: none

Price target (mean) 4.50

Next earnings

Aug 31, 2022

Expected Aug 31, 2022. Consensus EPS estimate 0.00.

Earnings history

Earnings

GBS recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Aug 31, 2022Jun 1, 2022-0.18———
May 10, 2022Mar 1, 2022-0.16———
Feb 10, 2022Dec 1, 2021-0.16———
Nov 11, 2021Sep 1, 20210.00———
May 14, 2021Mar 1, 20210.00———

About GBS Inc.

GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
gbs.inc

News

Your note

Sign in to keep a note on GBS — it syncs with the Stock Master app.

Insider holders

GBS insider holders
InsiderRelationLatest transactionDateShares held
BOYAGES STEVEN CONSTANTINEChief Executive OfficerStock Award(Grant)Oct 9, 202275,000
FISHER LAWRENCE BDirectorStock Award(Grant)Oct 9, 202215,000
GAVRILENKO VICTORIADirectorPurchaseMar 1, 202137
HURD JONATHAN SDirectorStock Award(Grant)Oct 9, 202215,000
LIFE SCIENCE BIOSENSOR DIAGNOSTICS PTY, LTD.UnknownSaleFeb 16, 20221,081,800
MARGELIS GEORGEDirectorStock Award(Grant)Oct 9, 202215,000

Institution ownership

GBS institution ownership
Holder% heldSharesValueReported
Geode Capital Management, LLC0.78%115,82554.81KJun 29, 2022
Renaissance Technologies, LLC0.75%111,90052.95KJun 29, 2022
State Street Corporation0.23%34,11516.14KJun 29, 2022
Susquehanna International Group, LLP0.23%33,69515.94KJun 29, 2022
HRT Financial LP0.14%20,5689.73KJun 29, 2022
IHT Wealth Management, LLC0.13%20,0009.46KJun 29, 2022

Fund ownership

GBS fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.76%113,11853.53KJun 29, 2022
Vanguard Extended Market Index Fund0.08%11,3885.39KJun 29, 2022
Advertisement